Candel Therapeutics Reports Officer/Director Changes
Ticker: CADL · Form: 8-K · Filed: Jun 6, 2025 · CIK: 1841387
| Field | Detail |
|---|---|
| Company | Candel Therapeutics, INC. (CADL) |
| Form Type | 8-K |
| Filed Date | Jun 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, corporate-governance, filing
Related Tickers: CADL
TL;DR
Candel Therapeutics (CADL) filed an 8-K detailing changes in directors and officers.
AI Summary
Candel Therapeutics, Inc. filed an 8-K on June 6, 2025, reporting events as of June 4, 2025. The filing indicates changes related to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes Regulation FD disclosures and financial statements/exhibits.
Why It Matters
Changes in a company's board of directors or executive officers can signal shifts in strategy, governance, or operational focus.
Risk Assessment
Risk Level: medium — Changes in key leadership roles can introduce uncertainty regarding future company direction and performance.
Key Players & Entities
- Candel Therapeutics, Inc. (company) — Registrant
- 001-40629 (company) — Commission File Number
- 52-2214851 (company) — IRS Employer Identification No.
- June 04, 2025 (date) — Earliest event reported
- June 6, 2025 (date) — Date of Report
FAQ
What specific changes were made regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, along with details on compensatory arrangements for these individuals.
When were these events reported?
The 8-K filing was made on June 6, 2025, reporting events that occurred as of June 4, 2025.
What are the key items covered in this 8-K filing?
The filing covers the departure/election/appointment of directors and officers, compensatory arrangements, Regulation FD disclosures, and financial statements/exhibits.
What is Candel Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 117 Kendrick St, Suite 450, Needham, Massachusetts, 02494.
What is the Commission File Number for Candel Therapeutics, Inc.?
The Commission File Number for Candel Therapeutics, Inc. is 001-40629.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 6, 2025 regarding Candel Therapeutics, Inc. (CADL).